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f Cincinnati, Cincinnati, OH, USAA B S T R A C TObjectives: This study compared actual use of individual statin drugs
to expected use based on their efficacy and safety profiles. Methods:
Five panels covering the years 1999 to 2008 from the National Health
and Nutrition Examination Survey provided interview, demographic,
and laboratory data for 8769 (365,503,838 weighted) people aged 20
years or older whowere not taking a statinmedication. An individual’s
risk for coronary heart disease and low-density lipoprotein (LDL) cho-
lesterol goal were determined, following the Adult Treatment Panel III
Cholesterol Guidelines. The percentage LDL cholesterol lowering re-
quired to reach his/her LDL cholesterol level goal was calculated. De-
pending on the amount of LDL cholesterol lowering needed and on if
the individual had a liver condition (i.e., enhanced risk of rhabdomyol-
ysis) statins were hypothetically prescribed. Predicted use was com-
pared to actual use by US Medicaid beneficiaries in the third quarter of
2009, obtained from the Medicaid State Drug Utilization Data main-
tained by the Centers for Medicare and Medicaid Services. Results: Re-
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doi:10.1016/j.jval.2011.07.005sults showed that 72.34% of the population was in the lowest coronary
heart disease risk group and that 86.30% required no statin therapy.
Among the people who did require LDL cholesterol lowering, a signifi-
cant majority (37.3 million or 10.22% of the population) needed 30%
lowering or less. Only 314,784 (0.09%) required LDL cholesterol lowering
of greater than 60%. Utilization shares based on safety and efficacy
were estimated at 19.26% (rosuvastatin), 18.67% (atorvastatin), 16.48%
(simvastatin), 16.30% (lovastatin), 14.93% (pravastatin), and 14.36% (flu-
vastatin). Conclusions: Actual statin use differed substantially from
predicted use. It may be appropriate to develop and maintain policies
that encourage use of less costly products that have essentially equiv-
alent safety profiles and efficacy.
Keywords: coronary heart disease, evidence-based medicine, hyper-
cholesterolemia, statins.
Copyright © 2012, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Approximately 17.6 million people aged 20 years and older in the
United States currently have coronary heart disease (CHD) [1]. CHD
can lead to other conditions, including angina, myocardial infarc-
tion, and stroke [2]. In 2006, CHD claimed the lives of 425,425
Americans, 67.4% of all lives lost to heart disease that year [1–3].
Diseases of the heart account for approximately 25% of all deaths
in people aged 65 to 84 years and approximately one-third of
deaths for those aged 85 years and older [4].
Risk factors for CHD may be classified as nonmodifiable, in-
luding age over 65 years and a positive family history, and
odifiable, including hypertension, hypercholesterolemia, type
diabetes, obesity, cigarette smoking, and a sedentary lifestyle
1–3]. Large-scale clinical studies have confirmed how impor-
ant hypercholesterolemia is as a risk factor for CHD. For every
0% reduction in cholesterol level, the risk of death from heart
isease decreases by 15% [5]. According to the Centers for Dis-
ase Control and Prevention, there are currently 35.7 million
mericans aged 20 years old and older with total blood choles-
* Address correspondence to: Christina M. L. Kelton, Professor of E
College of Business, University of Cincinnati, 414 Carl H. Lindner
0195 USA.
E-mail: chris.kelton@uc.edu.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.terol of 240 mg/dL and higher; 102.2 million have total choles-
terol 200 mg/dL and higher [1].
The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhib-
itors, also known as statins, are the most effective class of drugs
for lowering levels of serum low-density lipoprotein (LDL) choles-
terol and are considered first-line agents for patients who require
drug therapy to reduce LDL cholesterol levels [6,7]. In 1987, the first
statin, lovastatin (Mevacor), was approved by the Food and Drug
Administration (FDA). Six additional statins—atorvastatin (Lip-
itor), cerivastatin (Baycol), fluvastatin (Lescol), pravastatin (Prava-
chol), rosuvastatin (Crestor), and simvastatin (Zocor)—were ap-
proved between 1991 and 2002. An extended-release form of
lovastatin (Altoprev) was approved in 2002 [8]. See Table 1 for a list
f the statin drugs. Although statins enjoy generally favorable
afety profiles, they are associated with a rare but serious and
otentially fatal side effect, rhabdomyolysis (muscle pain and
eakness). In August 2001 cerivastatin was withdrawn from the
arket because of its association with rhabdomyolysis, especially
n patients who had been treated concurrently with gemfibrozil
9]. Individuals with a liver condition are at heightened risk for
mics and Adjunct Professor of Clinical Pharmacy, Carl H. Lindner
2925 Campus Green Drive, PO Box 210195, Cincinnati, OH, 45221-
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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33V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 2 – 3 8rhabdomyolysis. Thus, statins that are metabolized through the
liver (i.e., atorvastatin, rosuvastatin, and simvastatin) are some-
times (although not always because some physicians may pre-
scribe these statins for those with mild to moderate liver disease
while monitoring their hepatic panels) avoided for those with a
liver problem [10,11].
During the third quarter of 2009, the statins’ utilization shares
(shares of prescriptions) in the national Medicaid fee-for-service
market (a large market with publicly available data) were 25.75,
0.53, 5.04, 6.15, 17.12, and 45.40, for atorvastatin, fluvastatin, lova-
statin, pravastatin, rosuvastatin, and simvastatin, respectively
[12] (see the Appendix for calculation details in the Supplemental
Materials at: doi:10.1016/j.jval.2011.07.005). Pharmaceutical mar-
ket research firm IMS Health reported national utilization shares
for atorvastatin and simvastatin as 24.47 and 39.43, respectively
(also including ezetimibe and simvastatin [Vytorin] and ezetimibe
[Zetia] in the product mix) [13].
Differences in use across the statinsmay be partially explained
by product differences. First, research has shown that that there
are differences in efficacywith respect to lowering LDL cholesterol
levels [14,15]. There are also differences in rhabdomyolysis risk
[16,17]. Besides these basic clinical differences there may be other
possible reasons for the variation in use related to pharmaceutical
marketing efforts on the part of the statin manufacturers. The
objective of this study was to decompose actual use into two com-
ponents: evidence-based use predicted solely by the safety and
LDL cholesterol-lowering efficacy characteristics of the drug, and a
marketing component, including advertising, pricing, and recent
large clinical trials and cost-effectiveness studies undertaken by
the market leaders. By trying to predict use based on safety and
efficacy criteria alone, we hope potentially to provide the basis for
a new methodology for valuing medication that can be used for
managed care, Medicaid, Medicare, or hospital cost management.
Methods
Five 2-year panels (covering the years 1999–2008) from the Na-
tional Health and Nutrition Examination Survey (NHANES), which
targets the civilian noninstitutionalized US population, provided in-
terview, demographic, and laboratory data [18]. Each participant in
the survey represents a much larger group of people, so obtaining
national estimates requires appropriate weighting. All calculations
adhered to analytical techniques outlined in the NHANES docu-
entation to account for the weighting and complex sample de-
ign of the database [19]. We used SAS software (version 9.1.3,
pril 2006, SAS Institute Inc., Cary, NC) for all statistical analyses.
There were 8769 people across the five panels who met the fol-
Table 1 – Statins by US Food and Drug Administration (FDA
Generic name Brand name Branded-drug manu
Lovastatin Mevacor Merck
Simvastatin Zocor Merck
Pravastatin Pravachol Bristol Myers Squ
Fluvastatin Lescol Novartis
Atorvastatin Lipitor Pfizer
Cerivastatin† Baycol Bayer
Lovastatin Altoprev Andrx Laborator
Rosuvastatin Crestor AstraZeneca
Source: FDA Approved Drug Products at: http://www.accessdata.fda.
NA, not applicable.
* First quarter of entry in the US Medicaid fee-for-service market.
† Withdrawn from the US market in August 2001.owing inclusion criteria: 1) LDL laboratory results were reported; 2) nwere not taking a statin; 3) were 20 years of age or older; 4) were not
pregnant; and 5) had triglyceride levels below 500 mg/dL. Although
theoretically possible, it is highly unlikely that any individual patient
participated in more than one NHANES panel [19]. According to the
National Cholesterol Education Program’s Expert Panel onDetection,
Evaluation, andTreatmentofHighBloodCholesterol inAdults (Adult
Treatment Panel III) Guidelines, those individuals with triglyceride
levels greater than 500 mg/dL require control of those levels (e.g., by
niacin or fenofibrate) before a statin can be prescribed [6,7].
Based on NHANES data, the LDL cholesterol level at which to
begin drug therapy (based on the Adult Treatment Panel III Guide-
lines) was determined for each person [6,7,20]. Our protocol was as
follows: Those with CHD or diabetes (CHD equivalent) were as-
signed a cutoff for drug initiation (CDI) of LDL cholesterol  100
mg/dL, which assumes a role for lifestyle changes in reaching a
goal of 70 mg/dL for this group of people [20]. Other CHD equiva-
lents (such as peripheral arterial disease or abdominal aortic an-
eurysm [6,7]) could not be determined from the database. Those
with one or fewer risk factor were assigned a CDI  190 mg/dL,
where the five risk factors consideredwere 1) cigarette smoking; 2)
hypertension (blood pressure 140/90mmHg or taking antihyper-
tensive medication); 3) low high-density lipoprotein (HDL) choles-
terol (i.e.,  40 mg/dL); 4) family history of premature CHD; and 5)
age (men  45 years; women  55 years). If HDL cholesterol level
as greater than 60 mg/dL, then the person was assigned -1 risk
actor. For everyone else (those with two or more risk factors but
o CHD nor diabetes), a Framingham Point Score was calculated
nd a 10-year risk percentage determined from that score. The
ramingham Score depended on multiple factors: age, sex, smok-
ng status, total cholesterol, HDL, and systolic blood pressure [6,7].
hose with a 10-year risk less than 10%were assigned a CDI 160
g/dL. Those with a 10-year risk of 10% to 20% were assigned a
DI  130 mg/dL. Those with a 10-year risk of greater than 20%
ere assigned a CDI  100 mg/dL [20]. For each individual, the
ercentage LDL cholesterol lowering required was calculated us-
ng the following formula: [(LDL - CDI) / LDL] x 100%. If the value
as less than zero, then we assumed that no LDL cholesterol low-
ring, hence, no statin, was needed. If an individual responded
yes” to NHANES question MCQ160L asking if the person had ever
een told that he or she had a liver condition, then we assumed
hat he or shewas at a heightened risk for rhabdomyolysis.We did
ot take the liver condition per se into account in the assessment
f what statin or statins might be suitable.
Based on the literature for lipid lowering and risk of rhabdomy-
lysis, each of the six statins was designated as either “appropri-
te” or “not appropriate” for each of the individuals requiring a
tatin. A statinwas considered to be appropriate if the individual’s
proval date.
urer FDA approval date First quarter of generic
entry*
08-31-1987 2001 quarter 4
12-23-1991 2006 quarter 2
12-31-1991 2006 quarter 2
12-31-1993 NA
12-17-1996 NA
06-26-1997 NA
06-26-2002 NA
08-12-2003 NA
cripts/cder/drugsatfda/.) ap
fact
ibb
ies
gov/seeded LDL cholesterol lowering did not exceed the maximum
t
l
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highest daily dose (40 mg for rosuvastatin and 80 mg for the oth-
ers), as stated on the package insert [21–26]. For example, for any-
one without a liver condition needing LDL cholesterol lowering of
40%, four of the statins would be considered appropriate: all but
fluvastatin and pravastatin. Depending on how many of the st-
atins were found to be appropriate for a particular person, each
was assigned an equal prescription-probability share. For exam-
ple, if twodrugswere found to be appropriate for someonewithout
a liver condition needing 55% LDL cholesterol lowering, then each
would be assigned a share of 0.5. For this particular person, the
other four statins would be assigned a share of 0.0. Table 2 shows
he prescription odds for individuals falling into different LDL cho-
esterol-lowering categories.
Let Sij denote the share assigned to drug j for person i, where
j1
6 Sij 1 for all persons i.
The utilization share for drug j is found by totaling the
weighted prescription-probability shares of all people in the study
population. That is, USj iSij for statin j. Because the results may
be sensitive to the specific categories in Table 2, we also completed
our analysis based on two alternative lists of lipid- lowering max-
ima, across the statins, found in the literature [14,15], hence com-
pleting a small sensitivity analysis.
Results
Following the weighting procedure described in the NHANES doc-
umentation, we obtained a total of 365,503,838 weighted observa-
tions for the five panels taken together, representing, on average,
approximately 73 million per panel [19]. Table 3 shows demo-
graphic and clinical characteristics of the NHANES individuals
who comprised the study population. Recalling that none of the
individuals in the study was taking a statinmedication, onemight
expect to see an improvement in lab results over time as the like-
lihood increased that those with the greatest need for statin ther-
apy would be taking a statin. Indeed, mean LDL cholesterol level
dropped from 126.23 mg/dL in the 1999–2000 panel to 118.92
mg/dL in the most recent 2007–2008 panel. Concurrently, average
total cholesterol fell from 201.91 mg/dL to 197.71 mg/dL, whereas
the average triglyceride level fell from 127.64 mg/dL to 123.95 mg/
dL. Table 3 shows that although the risk of CHD has remained
Table 2 – Hypothetical odds of being prescribed a particula
lowering ability and risk to liver.
Elevated risk of
rhabdomyolysis
Percentage (%)
drop in LDL
required to reach
cutoff for drug
initiation
Atorvastatin Fluvas
4™™™™™™™™™™™™™™™™™™™™™™™
No 0%35 16.67 16.
35%37 20.00
37%40 25.00
40%47 33.33
47%60 50.00
%60
Yes 0%35 33.
35%37
37%40
40%47
47%60
%60relatively stable between 1% and 2% of the population, the risk ofdiabetes has clearly been rising. Whereas 3.79% of the population
had diabetes in the earliest panel, 5.83% reported having the dis-
ease in the latest NHANES survey. Furthermore, Table 3 shows a
substantial jump between the 2003–2004 and 2005–2006 panels in
the percentage of the population having a family history of pre-
mature heart disease. This jump is most likely due to a change in
the family-history survey question between the panels. Whereas
family referred to mother or father only in the earlier panels, it
included all close relatives in the later panels.
Pooling the individuals across the five panels, Table 4 shows
that 3.44% (12.6million out of 365.5million) reported having a liver
condition, hence an elevated risk for rhabdomyolysis. There were
9.94% in the highest CHD-risk group with CDI  100. The majority
of people (72.34%) fell into the lowest-risk group with CDI  190.
Out of the 365.5 million patients, Table 5 shows that 315.4 million
(86.30%) required no statin therapy. The remainder (50.1 million)
needed some LDL lowering; hence, could have benefited from sta-
tin therapy, according to the Adult Treatment Panel III Guidelines
[6,7,20]. Among the people who did require LDL cholestrol lower-
ing, a majority (37.3 million or 10.22% of the population) needed
lowering of 30% or less. Only 314,784 (0.09%) required LDL choles-
terol lowering of greater than 60%.
Estimated utilization shares are given in Table 6. Results are re-
ported for three different sets of LDL cholesterol-lowering percent-
ages. Based on their lipid-lowering abilities as well as their differen-
tial risks for liver- compromised individuals, and ignoring pricing or
other marketing considerations, we see that, based on their maxi-
mum LDL cholesterol-lowering capabilities as reported on their
package inserts (and used for the development of Table 2), rosuvas-
tatin has the highest share at 19.26%, followed by atorvastatin at
18.67%. Simvastatin and lovastatin command the second highest
shares at 16.48% and 16.30%, respectively. Fluvastatin and pravasta-
tin have shares of 14.36%and14.93%, respectively.Whereas the rank
order of the shares is the same if the Jensen [15] categorization (with
maximum LDL cholesterol-lowering potentials differing slightly
from levels listed on the package inserts) is used, there is an interest-
ing reversal in rank for lovastatin and simvastatin following the Law
et al. [14], classification (yet a third slight variation from what the
package inserts indicate), in which simvastatin’s maximum lipid-
lowering ability is given at 40%. In the Law et al. [14] classification,
because lovastatin and simvastatin both have the same upper limit,
and because lovastatin, and not simvastatin, is considered appropri-
ate in this study forpatientswitha liver condition, its predicteduse is
tin based on low-density lipoprotein (LDL) cholesterol-
Statin
Lovastatin Pravastatin Rosuvastatin Simvastatin
™™™™™™™™™™™™™™™™™™™™™™ % ™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™3
16.67 16.67 16.67 16.67
20.00 20.00 20.00 20.00
25.00 25.00 25.00
33.33 33.33
50.00
100.00
33.33 33.33
50.00 50.00
100.00
100.00
100.00
100.00r sta
tatin
™™™™™
67
33higher than that for simvastatin [14].
moth
35V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 2 – 3 8Nevertheless, the three sets of results do not differ much
from each other, suggesting a high degree of robustness in the
approach.
Discussion
The six statins available in the US market have different safety
and efficacy profiles, giving prescribers a choice of medication
depending on patient characteristics. Some difference in use
among the statins is expected based on evidence regarding
safety and LDL cholesterol-lowering efficacy, and the utilization
shares calculated in this study reflect those differences. If the
drugs were identical in safety and efficacy, we would expect
each drug to have an identical 16.67% share of all statin pre-
scriptions. This result was not observed. The actual pattern of
statin use, however, differs substantially from the pattern pre-
dicted in this study (Table 6). The direct implication of this re-
search is that prescribers and payers are affected by more than
just safety and lipid-lowering efficacy. Indeed, a substantial
Table 3 – Characteristics of study population by National H
1999–2008.
Characteristic
1999–2000
No. of persons 64,883,696
4™™™™™™™™™™™™™™™™
Demographics
Mean age 43.820.46
Percent men 48.611.65
Laboratory results
Mean triglyceride level (mg/dL) 127.642.12
Mean total cholesterol (mg/dL) 201.911.28
Mean systolic blood pressure (mmHg) 119.792.12
Mean HDL (mg/dL) 50.190.48
Mean LDL (mg/dL) 126.231.17
Risk factors
Percent with CHD 1.260.28
Percent with diabetes 3.790.59
Percent with family history of premature
CHD*
7.830.97
Percent smokers 24.211.44
CHD, coronary heart disease; HDL, high-density lipoprotein choleste
* The NHANES survey question regarding family history of prematur
panel, becoming more inclusive with close relatives as opposed to
Table 4 – Breakdown of Persons not receiving statin therap
initiation across five National Health and Nutrition Examin
Cutoff for drug
initiation*
Persons asked if they had
People responding “Yes”
across 5 NHANES panels
n %
100 2,268,129 18.02
130 1,082,855 8.60
160 1,517,261 12.05
190 7,721,304 61.33
Total 12,589,550
* Based on Adult Treatment Panel III Guidelines.
† Question MCQ160L from NHANES questionnaire.amount of marketing effort has accompanied the statin drug
class with the express purpose of differentiating among the
drugs.
According to Donohue et al. [27] the statin drug class had the
third highest (following antidepressants and proton pump inhibi-
tors) promotional spending ($859million) in 2005. Out of this total,
52% was spent on detailing, 11% at professional meetings and
events, and 34% on direct-to-consumer (DTC) advertising [27]. In
2008, Pfizer spent $107.9 million on DTC advertising for atorvasta-
tin alone; in 2009, it spent $247.1 million. Meanwhile, AstraZeneca
spent $114.2 million on DTC advertising for rosuvastatin in 2008
and $129.4 million in 2009 [28]. From 2000 to 2005, Merck adver-
tised simvastatin heavily to consumers but did not invest in ad-
vertising for lovastatin, its earlier contribution to the category that
faced generic competition beginning in 2001.
Pricing strategymay also have played a role in influencing use.
With the exception of simvastatin, which was matched in price to
lovastatin when it entered the statin market, the other market
entrants eachwere priced lower than the previous entrant; that is,
and Nutrition Examination Survey (NHANES) panel,
NHANES panel
1–2002 2003–2004 2005–2006 2007–2008
003,749 73,616,516 75,652,311 79,347,566
™™™™™™™™™™™™™™™™™™™™™™™™™ -Meanstandard error ™™™™™™™™™™™™™™™™™™3
.750.41 44.650.40 44.950.41 44.790.38
.341.46 47.891.47 49.781.47 47.371.39
.401.96 128.402.00 124.491.98 123.951.83
.791.13 199.231.13 198.741.15 197.711.83
.750.78 114.900.90 116.070.77 114.460.75
.790.43 54.500.46 56.060.48 54.000.43
.531.01 119.061.01 117.781.03 118.920.93
.310.25 2.090.34 1.530.32 1.340.25
.100.53 5.000.58 5.270.59 5.830.58
.640.73 7.990.83 17.261.13 13.630.94
.471.27 25.441.29 27.141.32 22.781.12
L, low-density lipoprotein cholesterol.
rt disease changed between the 2003–2004 panel and the 2005–2006
er or father only.
low-density lipoprotein cholesterol level cutoffs for drug
n Survey (NHANES) panels, 1999–2008.
er condition† Total
ople responding “No”
ross 5 NHANES panels
n % n %
,064,624 9.65 36,332,754 9.94
,342,127 6.05 22,424,982 6.14
,832,927 11.57 42,350,189 11.59
,674,611 72.73 264,395,915 72.34
,914,288 365,503,838ealth
200
72,
™™™™™
43
49
127
198
117
51
121
1
4
6
25
rol; LD
e heay by
atio
a liv
Pe
ac
34
21
40
256
352
36 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 2 – 3 8pravastatin was priced lower than lovastatin, fluvastatin lower
than pravastatin, atorvastatin lower than fluvastatin, and cerivas-
tatin lower than atorvastatin [29]. This strategy may have been
helpful in a category in which it was difficult to compete on effi-
cacy or safety characteristics alone.
Moreover, pharmaceutical companies, particularly Pfizer and
AstraZeneca, have sponsored large clinical trials establishing effi-
cacy of their statins with respect to additional clinical endpoints
[30–36]. In fact, following the Treating to New Targets trial, the
FDA approved five additional indications for atorvastatin, includ-
ing reduced risk of nonfatal myocardial infarction, reduced risk of
fatal and nonfatal strokes, reduced risk of revascularization pro-
cedures, reduced risk of hospitalization for congestive heart fail-
ure, and reduced risk of angina. These large trials and new-indi-
cation approvals clearly have a positive effect on use. However,
due to the absence of similar studies for the other statins, the
evidence does not support superiority with respect to these vari-
ous endpoints.
Cost-effectiveness studies, again primarily sponsored by the
market leaders, suggest that the leading statins have good value
[37–39], although, again, they do not show that the other statins do
not. Finally, at the writing of this article, three of the statins are
available as generics (lovastatin since the end of 2001, and prava-
statin and simvastatin since 2006), whereas the others are not. The
large price difference between branded and generic drugs may
encourage cost-conscious payers to favor the generics.
The indirect implication of this research is that there are tre-
mendous cost savings available to payers today and have been
since generic lovastatin’s initial availability in 2001. During the
Table 5 – Percentage low-density lipoprotein (LDL) choleste
across five National Health and Nutrition Examination Sur
Percentage drop
in LDL required
to reach cutoff
for drug
initiation*
Persons asked if they ha
People responding “Yes”
across five NHANES
panels
n %
No drop required 10,287,033 81.71
0-30 1,720,259 13.66
30-40 394,921 3.14
40-50 158,093 1.26
50-60 8,839 0.07
60 204,050 0.16
Total 12,589,550
* Based on Adult Treatment Panel III Guidelines.
† Question MCQ160L from NHANES questionnaire.
Table 6 – Estimated utilization shares in the statin therape
Source for
maximum LDL
lowering
percentages
Atorvastatin Fluvastatin
4™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Package inserts [21–26] 18.67 14.36
Law et al. [14] 18.57 13.95
Jensen [15] 18.45 14.36
Actual Medicaid
utilization shares*
25.75 0.53
LDL, low-density lipoprotein cholesterol.
* For further information, see Supplemental Material at: doi:10.1016/j.jvalthird quarter of 2009, Medicaid’s average (prerebate) reimburse-
ment for a prescription of atorvastatin was $123 and of rosuvasta-
tin was $125, whereas that for simvastatin was slightly less than
$10. See the Appendix in the Supplemental Materials at: doi:
10.1016/j.jval.2011.07.005 for calculation methodology. (Although
there are some price differences across the doses, it is still the case
that even high-dose generics offer considerable cost savings
relative to low-dose branded statins). According to our results (see
Table 5), there are relatively few people needing the high lipid-
lowering efficacy that atorvastatin and rosuvastatin provide. For
cost savings, almost everyone could be taking one of the available
inexpensive generics without sacrificing any efficacy or safety.
The potential cost savings to a large payer can easily be calcu-
lated from our results. For example, during the third quarter of
2009 Medicaid spent $73.7 million on 1.2 million statin prescrip-
tions for its fee-for-service beneficiaries. Of this $73.7 million,
53.22% was spent on atorvastatin, 0.96% on fluvastatin, 35.73% on
rosuvastatin, 7.37% on simvastatin (Zocor and generic simvastatin
together), 1.36% on pravastatin (Pravachol and generic pravastatin
together), and 1.36% on lovastatin (Mevacor, Altoprev, and generic
lovastatin altogether). As an indication of howmuch savings were
available for Medicaid that quarter, we tried to determine how
much Medicaid would have had to spend on statin therapy if ev-
eryone enrolled in Medicaid during the third quarter of 2009 re-
ceiving statin therapy were prescribed the cheapest appropriate
drug. To conduct such a thought experiment, we assumed 1) that
the distribution of Medicaid beneficiaries across the categories in
Table 4was equivalent to the NHANES distribution, and 2) that the
per-prescription (prerebate) prices were as calculated from the
owering required for persons not taking statin therapy
NHANES) panels, 1999–2008.
iver condition†
eople responding “No”
across five NHANES
panels
Total
n % n %
5,152,494 86.47 315,439,527 86.30
5,623,123 10.09 37,343,382 10.22
6,589,933 1.87 6,984,854 1.91
4,112,365 1.17 4,270,458 1.17
1,141,995 0.32 1,150,834 0.31
294,379 0.08 314,784 0.09
2,914,289 365,503,839
drug class.
Statin
statin Pravastatin Rosuvastatin Simvastatin
™™™™™™™™™™™™™™™™ % ™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™3
6.30 14.93 19.26 16.48
8.21 13.95 20.04 15.28
6.47 14.36 19.04 17.32
5.04 6.15 17.12 45.40rol l
vey (
d a l
P
30
3
35utic
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™™™™™
1
1
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terials at: doi:10.1016/j.jval.2011.07.005): $123.38 for atorvastatin,
$107.03 for fluvastatin, $14.84 for generic lovastatin, $12.85 for ge-
neric pravastatin, $124.59 for rosuvastatin, and $9.55 for generic
simvastatin, respectively. Our calculations show required spend-
ing for Medicaid during third quarter 2009 as $19.0 million for a
potential savings of $54.7 million without compromising safety or
efficacy. Those who required the lipid-lowering efficacy of atorv-
astatin or rosuvastatinwould still receive the drug. Note that these
results are sensitive to the assumption thatMedicaid beneficiaries
have a similar distribution of required LDL cholesterol lowering to
that of the national population. To the extent that low-income,
publicly-insured individuals require more aggressive therapy,
then our results may overstate the savings available to Medicaid.
Our findings illustrate the value of comparative-effectiveness
research rather than suggest simply that there are often savings
available in the use of generic drugs. The latter point is well
known. Both private and public prescription drug plans already
encourage the use of generic drugs through a variety of mecha-
nisms. For example, state Medicaid programs encourage their use
by requiring a lower copayment for a generic than a brand-name
drug, by including generic drugs on the state’s preferred drug list,
by educating physicians on the use of generics, or by providing a
higher dispensing fee to pharmacists who dispense generic drugs
[40].Moreover, according to several previous studies,Medicaid has
been reasonably successful in switching patients to generic drugs
from their branded counterpart fairly quickly following the patent
expiration of the branded drug [41–43]. Payers, however, find it
ore difficult to enforce the use of some drugs over others within
drug class (e.g., some statins over other statins) or one class of
rugs over another (e.g., angiotensin-converting-enzyme inhibi-
ors vs. the currently much costlier angiotensin receptor blockers
or hypertension and heart failure) [44]. Whereas prior authoriza-
tion policies could be developed, they are expensive to implement
[45]. Payers require solid comparative-effectiveness evidence to
justify the costs of such policies.
Limitations
At this point, we do not know to what extent the methodology we
have developed and applied can be generalized. In the case of the
statin class, there are several studies in the literature that make
head-to-head comparisons across all the statins on the basis of
efficacy [14,15] and safety [16,17]. These studies provided the foun-
dation for estimating expected statin use based on clinical facts
alone. These key studies may not be available for other drug
classes. For those classes, especially for those where there are a
number of important risk factors that need to be considered simul-
taneously, an expert panel could be assembled to come up with a
table similar to Table 2.
Another potential concern is that use was predicted for indi-
viduals who were currently not taking a statin medication,
whereas actual use is, of course, based on those taking medica-
tion. Hence, we redid our analysis using only the first twoNHANES
panels (1999–2000 and 2001–2002), when the statin class was still
relatively new. Because we found almost identical results, we de-
cided to present the results from the five-panel analysis.
Moreover, we measured efficacy as LDL cholesterol lowering,
the indication for which all the statins received their initial FDA
approval. LDL cholesterol, however, is a surrogate endpoint and
not a final outcome like stroke or myocardial infarction preven-
tion. To the extent that such outcome data were available for all of
the statins, predicted statin use could be based on prevention sta-
tistics.
Finally, like all survey databases, the NHANES database is sub-
ject to recall bias. Whether or not an individual had a liver condi-
tion, was considered a smoker, and so forth, was determined by
his or her response to a survey question.Conclusions
Actual statin use by Medicaid beneficiaries during the third quar-
ter of 2009 differed significantly from use predicted from lipid-
lowering and safety considerations using the NHANES database.
This difference may be explained in part by varying pricing strat-
egies and marketing practices among the statin manufacturers
and in part by differences in population characteristics between
Medicaid (in 2009) and a more nationally representative group
of patients (during the period 1999–2008). It may be appropriate
to develop and maintain policies that encourage use of less
costly products that have essentially equivalent safety profiles
and efficacy.
Acknowledgments
The authors thank Dr. Pamela C. Heaton for her comments on
pharmaceutical marketing that inspired the study and an anony-
mous referee for this journal for providing useful suggestions. An
earlier version of this work was presented as an unpublished
poster at 1) the 13th Annual European Congress of the Interna-
tional Society for Pharmacoeconomics and Outcomes Research in
Prague, Czech Republic, November 6 to 9, 2010, where it won a
finalist award; and 2) the 45th Midyear Clinical Meeting & Exhibi-
tion of the American Society of Health-System Pharmacists in
Anaheim, California, December 5 to 9, 2010.
Dr. Keltonwas a co-investigator on research studies sponsored
by Novartis, Janssen Ortho-McNeil, and Eli Lilly. None involved
statin drugs. Dr. Martin Boone was a coinvestigator on research
studies sponsored by Novartis and Eli Lilly. None involved statin
drugs. Dr. Guo was a principal or coinvestigator on research stud-
ies sponsored by Novartis, AstraZeneca, Bristol-Myers Squibb,
Janssen Ortho-McNeil, and Eli Lilly. None involved statin drugs.
Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at doi:10.1016/j.jval.2011.07.005,
or if hard copy of article, atwww.valueinhealthjournal.com/issues
(select volume, issue, and article).
R E F E R E N C E S
[1] Lloyd-Jones D, Adams RJ, Brown TM, et al. American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Heart
disease and stroke statistics 2010 update: a report from the American
Heart Association. Circulation 2010;121:e46–215.
[2] National Institutes of Health Medline Plus. Coronary heart disease.
Available from: http://www.nlm.nih.gov/medlineplus/ency/article/
007115.htm. [Accessed October 28, 2010].
[3] Brown JR, O’Connor GT. Coronary heart disease and prevention in the
United States. N Engl J Med 2010;362:2150–3.
[4] Xu J, Kochanek KD, Murphy SL, et al. Deaths: final data for 2007.
Available from: http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_
19.pdf. [Accessed January 2, 2011].
[5] Gould AL, Rossouw JE, Santanello NC, et al. Cholesterol reduction
yields clinical benefit: impact of statin trials. Circulation 1998;97:
946–52.
[6] Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III). Executive summary
of the third report of the National Cholesterol Education Program
(NCEP). JAMA 2001;285:2486–97.
[7] Expert Panel on Detection, Evaluation, and Treatment of High Blood
Cholesterol in Adults (Adult Treatment Panel III). Third report of the
National Cholesterol Education Program (NCEP). Circulation 2002;106:
3143–421.
[[
[
[
[
[
[
[
[
38 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 3 2 – 3 8[8] Food and Drug Administration. FDA approved drug products.
Available from: http://www.accessdata.fda.gov/scripts/cder/
drugsatfda/. [Accessed January 1, 2011].
[9] Angelmar R. The rise and fall of Baycol/Lipobay. J Med Marketing 2007;
7:77–88.
[10] Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of
the potential over-the-counter statins simvastatin, lovastatin,
fluvastatin and pravastatin. Clin Pharmacokinet 2008;47:463–74.
11] Singhvi SM, Pan HY, Morrison RA, Willard DA. Disposition of
pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor,
in healthy subjects. Br J Clin Pharmacol 1990;29:239–43.
12] Centers for Medicare & Medicaid Services. State drug utilization data.
Available from: http://www.cms.gov/MedicaidDrugRebateProgram/
SDUD/list.asp. [Accessed October 17, 2010].
13] IMS Health. Top therapeutic classes by U.S. dispensed prescriptions
and Top 15 U.S. pharmaceutical products by dispensed prescriptions.
April 6, 2010. Available from: http://www.imshealth.com/. [Accessed
October 17, 2010].
14] Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low
density lipoprotein cholesterol, ischaemic heart disease, and stroke:
systematic review and meta analysis. BMJ 2003;326:1423–7.
15] Jensen B. Lipid lowering therapy: dyslipidemia comparison chart.
2003. Available from: http://www.sdl.academic.chula.ac.th/Misc/
Offline%20Resources/Lipids/Cholesterol%20Rxfiles%20cht.pdf.
[Accessed February 12, 2011].
16] Omar MA, Wilson JP. FDA adverse event reports on statin-associated
rhabdomyolysis. Ann Pharmacother 2002;36:288–95.
17] Hendelmam K, Alvan G, Ohagen P, Dahl M. Muscle toxicity with
statins. Pharmacoepi and Drug Safety 2010;19:223–31.
18] Centers for Disease Control and Prevention. Key concepts about NHANES
survey design. Available from: http://www.cdc.gov/nchs/tutorials/
nhanes/SurveyDesign/SampleDesign/Info1.htm. [Accessed January 1,
2011].
19] Gossett J, Jo C, Simpson P. 2006. U.S. health and nutrition: SAS survey
procedures and NHANES. Proceedings, 31st Annual SAS Users Group
International Conference, March 26-29, 2006, San Francisco,
California. SUGI 31 Paper 140-31. Available from http://www2.sas.com/
proceedings/sugi31/140-31.pdf. [Accessed January 1, 2011].
[20] Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical
trials for the National Cholesterol Education Program Adult Treatment
Panel III Guidelines. Circulation 2004;110:227–39.
[21] Crestor [package insert]. Wilmington, DE: AstraZeneca
Pharmaceuticals LP. February 2010.
[22] Lescol [package insert]. East Hanover, NJ. Novartis Pharmaceutical
Corporation. October 2006.
[23] Lipitor [package insert]. New York, NY: Pfizer, Inc. June 2009.
[24] Mevacor [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.
October 2009.
[25] Pravachol [package insert]. Princeton, NJ: Bristol-Myers Squibb
Company. February 2007.
[26] Zocor [package insert]. Whitehouse Station, NJ: Merck & Co., Inc. May
2010.
[27] Donohue JM, Cevasco M, Rosenthal MB. A decade of direct-to-
consumer advertising of prescription drugs. N Engl J Med
2007;357:673–81.
[28] Advertising Age Data Center. 100 leading national advertisers ranked
by total U.S. advertising spending in 2009. Available at:
http://www.adage.com. [Accessed October 17, 2010].[29] Jing Y, Kelton CML, Guo JJ, et al. Price and utilization of statins in the
Medicaid program. Drug Benefit Trends 2006;18:580–92.
[30] Ridker P, Danielson E, Fonseca F, et al. Rosuvastatin to prevent
vascular event in men and women with elevated C-reactive protein.
N Engl J Med 2008;359:2195–207.
[31] Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and
cardiovascular events in patients undergoing hemodialysis. N Engl
J Med 2009;360:1395–407.
[32] LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets
(TNT) Investigator. Intensive lipid lowering with atorvastatin in
patients with stable coronary disease. N Engl J Med 2005;352:1425–35.
[33] Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin
on hospitalizations for heart failure: subgroup analysis of the Treating
to New Targets (TNT) study. Circulation 2007;115:576–83.
[34] Amarenco P, Goldstein L, Szarek M, et al. Effects of intense LDL
lipoprotein reduction in patients with stroke or TIA. Stroke 2007;38:
3198–204.
[35] Hall AS, Jackson BM, Farrin AJ, et al. A randomized, controlled trial of
simvastatin versus rosuvastatin in patients with acute myocardial
infarction: the Secondary Prevention of Acute Coronary
Events–Reduction of Cholesterol to Key European Targets Trial. Eur
J Cardiovasc Prev Rehabil 2009;16:712–21.
[36] Ward S, Jones ML, Pandor A, et al. A systematic review and economic
evaluation of statins for the prevention of coronary events. Health
Technol Assess 2007;11:1–339.
[37] Costa-Scharplatz M, Ramanathan K, Frial T, et al. Cost-effectiveness
analysis of rosuvastatin versus atorvastatin, simvastatin, and
pravastatin from a Canadian health system perspective. Clin Ther.
2008;30:1345–57.
[38] Hirsch M, O’Donnell J, Olsson A. Rosuvastatin is cost-effective
compared with atorvastatin in reaching cholesterol goals. Inter
J Cardiol 2005;104:251–6.
[39] Ohsfeldt RL, Gandhi SK, Fox KM, et al. Effectiveness and cost-
effectiveness of rosuvastatin, atorvastatin, and simvastatin among
high-risk patients in usual clinical practice. Am J Manag Care 2006;12:
S412–23.
[40] Kaiser Commission on Medicaid and the Uninsured. Medicaid
outpatient prescription drug benefits: findings from a national survey,
2003. Available from: http://www.kff.org/medicaid/upload/Medicaid-
Outpatient-Prescription-Drug-Benefits-Findings-from-a-National-
Survey-2003.pdf. [Accessed February 12, 2011].
[41] Ferrand Y, Kelton CML, Guo JJ, et al. Using time-series intervention
analysis to understand U.S. Medicaid expenditures on antidepressant
agents. Res Soc Admin Pharm 2011;7:64–80.
[42] Guo JJ, Kelton CML, Pasquale MK, et al. Price and market-share
competition of anti-ulcer gastric medications in the Ohio Medicaid
market. Int J Pharma Medicine 2004;18:271–82.
[43] Guo JJ, Kelton CML. Chapter 20: Competition between brand-name and
generic drugs. In: Fulda TR and Wertheimer A, eds. Handbook of
Pharmaceutical Public Policy, 1st ed. New York: Haworth Press, Inc,
2007: 395–416.
[44] Bian B, Kelton CML, Guo JJ, Wigle PR. Ace inhibitor and ARB utilization
and expenditures in the Medicaid Fee-For-Service Program from 1991
to 2008. J Manag Care Pharm 2010;16:671–9.
[45] Reissman D. Prior authorization: what does it really cost? Health Care
News. December 1, 2001. Available at: http://www.heartland.org/
healthpolicy-news.org/article/421/Prior_Authorization_What_Does_it_
Really_Cost.html. Accessed June 25, 2011.
